Lifecore Biomedical agrees to be acquired by Webster Equity Partners for $6.28 a share plus CVR
LFCR•Webster Equity Partners agreed to acquire Lifecore Biomedical for $6.28 per share in cash at closing, with total potential consideration of up to $9.67 per share if all CVR milestones are met. The deal could be worth up to $663.7 million, and closing is targeted for the end of Q4 2026.
1. Deal terms
Webster Equity Partners agreed to acquire Lifecore Biomedical for $6.28 per share in cash at closing. Each share will also receive one non-tradable contingent value right, with up to $160 million in aggregate cash payouts tied to performance milestones. Total potential consideration is up to $9.67 per common share equivalent if all milestones are met.
2. Expected completion
The deal is valued at up to $663.7 million, assuming full achievement of the milestones. Closing is targeted for the end of Q4 2026, and Lifecore shares are expected to be delisted from Nasdaq upon completion.
